Nanobiotix Appoints CordenPharma as Manufacturing Partner

March 18, 2015
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-04-01-2015, Volume 11, Issue 4

The manufacture and scale up production mark a significant milestone in the commercialization route of Nanobiotix lead product, NBTXR3.

Nanobiotix, a late clinical stage nanomedicine company specializing in the development of cancer treatments, has appointed CordenPharma as its manufacturing partner. The new manufacturing line is located in France.

The manufacture and scale up production mark a significant milestone in the commercialization route of Nanobiotix lead product, NBTXR3. Demand for NBTXR3 is expected to increase, particularly from clinical trials in Europe and the United States.

CordenPharma, an international full service CMO for pharma and biotech companies, is recognized by EMA and FDA for its eight cGMP facilities across Europe and the United States. The company has a good track record with the regulators and its facilities are regularly inspected.

Laurent Lévy, chief executive officer at Nanobiotix, commented in a press release that finding the right manufacturing partner is essential because ensuring quality and sufficient levels of supply is fundamental for meeting market demands and supporting the growth of the company.

NBTXR3, Nanobiotix’s lead product in the NanoXray portfolio, comprises hafnium oxide nanoparticles that can be injected directly into tumor. Used alongside radiotherapy, these nanoparticles absorb X-rays have the potential to significantly enhances the radiation dose within the cancer cells without increasing the dose to the surrounding healthy tissues. NBTXR3 has the potential to cause a paradigm shift in cancer therapy with significant clinical benefit for patients.

In November 2014, Nanobiotix announced its global clinical development plan. In addition to soft tissue sarcoma and head and neck cancer, the plan now includes metastatic liver cancer, hepatocellular carcinomas, and prostate cancer. In the second half of 2015, the liver cancers and high-risk prostate cancer programs are anticipated to enter the clinical stage.

Source: Nanobiotix